GLP-1 & Incretin Science

The GIP Paradox: Why Agonism and Antagonism Both Produce Weight Loss

UKPWritten and published by UK Peptides3 min readUpdated 4 cited sources

The short answer

Tirzepatide activates the GIP receptor and produces up to 22.5% weight reduction. Maridebart cafraglutide blocks the same receptor and also produces substantial reduction. Both are paired with GLP-1 agonism, both work, and whether GIPR should be agonised or antagonised for obesity remains unresolved.

Key facts

GIPR agonist example
Tirzepatide (with GLP-1 agonism)
GIPR antagonist example
Maridebart cafraglutide (MariTide)
Shared component
Both include GLP-1 receptor agonism
Status of the question
Unresolved, but now tested directly
First direct comparison
Davies 2026, in mice (PMID 41287212)
Leading hypothesis
Antagonism may improve tolerability
Key review
Annu Rev Nutr 2026 (PMID 42166683)

The contradiction

Tirzepatide is a dual agonist: it activates both the GIP and GLP-1 receptors, and it produces greater weight reduction than GLP-1 agonism alone. Maridebart cafraglutide is a bispecific molecule that does the opposite at GIPR: a monoclonal antibody that blocks the receptor, conjugated to two GLP-1 agonist peptides. It also produces pronounced dose-dependent weight reduction. So two compounds do opposite things at the same receptor, and both appear to work.

Why this is not simply an error somewhere

It would be tidier if one programme rested on a misreading, but both have clinical data. Tirzepatide is an approved medicine with pivotal trials behind it. The GIPR antagonist approach was reported in Nature Metabolism in 2024 with preclinical and Phase 1 evidence of dose-dependent reduction and an acceptable tolerability profile. A 2026 review in the Annual Review of Nutrition addresses the paradox directly rather than dismissing either side.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

Hypothesis one: it is about tolerability, not efficacy

The most discussed explanation is that GIPR antagonism reduces nausea. If blocking GIPR improves tolerability of a co-administered GLP-1 agonist, then more GLP-1 agonism can be delivered before adverse effects force a dose reduction. On that reading the antagonist is not producing weight loss through GIPR at all. It is removing the ceiling on how much GLP-1 signalling a person can tolerate. The weight reduction would still be GLP-1-driven.

Hypothesis two: chronic agonism becomes functional antagonism

Sustained agonism at a G-protein-coupled receptor commonly causes desensitisation and receptor internalisation. If continuous GIPR agonism downregulates the receptor, then long-term agonism and pharmacological blockade could converge on a similar functional state (reduced GIPR signalling) by different routes. This would make the paradox apparent rather than real, but it is a hypothesis rather than a demonstrated mechanism.

Hypothesis three: central and peripheral GIPR do different things

GIP receptors are expressed in adipose tissue, pancreas and brain, including regions relevant to appetite. If the receptor's role differs by tissue, a molecule reaching central receptors could produce an effect opposite to one acting principally in the periphery. Molecule size and blood-brain-barrier penetration then matter as much as whether a compound agonises or antagonises.

What emerging data suggests

Work reported through 2026 supports the notion that GIPR agonism and antagonism can each provide additive weight reduction when combined with a GLP-1 receptor agonist. A 2026 comparison in male mice examined the two approaches head to head metabolically. This does not yet resolve which is preferable in humans, and it is unusual for a field to advance two opposite pharmacologies this far without settling the question.

Why it matters for reading the field

Any confident claim that GIP agonism is the reason tirzepatide outperforms semaglutide should be read carefully. It is consistent with the data and it may well be right, but a competing programme built on the opposite premise is producing results too. The honest position is that adding GIPR engagement to GLP-1 agonism helps, and the direction of that engagement is not settled.

The first direct comparison

Until recently the two strategies had only ever been compared across separate trials of separate compounds in separate populations, a comparison that cannot settle anything. Davies and colleagues published a metabolic comparison of GIPR agonism against GIPR antagonism in male mice in Diabetes, Obesity and Metabolism in February 2026: both directions, one model, matched conditions. It is a rodent study and it does not resolve the human question, but it is the first time the two have been placed side by side rather than inferred across trials.

Quick reference

TirzepatideMaridebart cafraglutide
GIPR actionAgonistAntagonist
GLP-1R actionAgonistAgonist
FormatSingle peptideAntibody + 2 peptides
StatusApprovedInvestigational
OutcomeWeight reductionWeight reduction

Frequently asked questions

How can blocking and activating the same receptor both work?

That is the open question. Leading explanations are that antagonism improves tolerability so more GLP-1 can be given, that chronic agonism desensitises the receptor into a similar state, or that central and peripheral GIP receptors differ in role.

Does this mean GIP agonism is not why tirzepatide works better?

It means the inference is less secure than it appears. Adding GIPR engagement clearly helps; the direction of that engagement is unresolved.

Is either approach proven superior?

No. Tirzepatide has approval and pivotal data; the antagonist approach has preclinical and early clinical evidence. No head-to-head resolution exists.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.